My Watchlist

Top Indices

NASDAQ Composite

Standard & Poors 500

My Portfolio

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

27.82 +0.23 (+0.83%)

Delayed Quote Updated: 1:33 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

63 64 Next >

Stock Market Today, March 12: Hims and Hers Health Drops After Rally Sparks Profit Taking ↗

March 12, 2026

On March 12, 2026, investors weighed profit-taking against a high-stakes pivot toward branded obesity drugs and telehealth growth.

Via The Motley Fool

Topics Intellectual Property Stocks

Does This Deal Make Novo Nordisk Stock a Buy? ↗

March 12, 2026

Not many things have gone right for Novo Nordisk recently, but this is one of them.

Via The Motley Fool

Topics Intellectual Property Lawsuit

The New Era of Hims & Hers Health (HIMS): Navigating the Branded Obesity Drug Pivot

March 12, 2026

As of March 12, 2026, the healthcare landscape has been fundamentally reshaped by the intersection of digital platforms and the "obesity gold rush." At the center of this transformation is Hims & Hers...

Via Finterra

Why Hims & Hers Health (HIMS) Stock Is Surging In Thursday's Premarket ↗

March 12, 2026

HIMS stock jumps in Thursday premarket. Explore how the Novo Nordisk partnership and a 46% short float are driving Hims & Hers Health Inc (NYSE: HIMS) higher.

Via Benzinga

1 Value Stock with Exciting Potential and 2 We Ignore

March 12, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

These stocks are making the most noise in today's session. ↗

March 11, 2026

Via Chartmill

Hims & Hers Stock Skyrockets as Landmark Settlement with Novo Nordisk Ends Weight-Loss Drug War

March 11, 2026

The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant...

Via MarketMinute

Topics Economy Intellectual Property Lawsuit

HIMS Stock Jumps 14% – Barclays Says Market Is Underestimating Opportunity From New Products ↗

March 11, 2026

Brokerages have turned bullish on HIMS since its deal with Novo Nordisk earlier this week, with Barclays raising the stock’s price target to $29.

Via Stocktwits

Topics Intellectual Property Lawsuit

Short Seller Who Bet Against Hims & Hers Now Says Its CEO 'Wiped The Floor' With Novo Nordisk ↗

March 11, 2026

Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages and could face legal risks tied to patents.

Via Stocktwits

Topics Bankruptcy Fraud Intellectual Property

3 Big Reasons to Love Hims & Hers Health (HIMS)

March 11, 2026

Hims & Hers Health has gotten torched over the last six months - since September 2025, its stock price has dropped 55.2% to $23.21 per share. This may have i...

Via StockStory

Hims & Hers Names Kathryn Beiser as Chief Communications Officer

March 10, 2026

From Hims & Hers

Via Business Wire

Asset Manager Exits Shares of Hims & Hers Health ↗

March 10, 2026

Hims & Hers Health has struggled, but it just inked a new partnership with Novo Nordisk.

Via The Motley Fool

Topics Regulatory Compliance

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal ↗

March 10, 2026

Via MarketBeat

Disrupting the Pharmacy: A Deep-Dive into Hims & Hers Health (HIMS) in 2026

March 10, 2026

As of March 10, 2026, the telehealth landscape has undergone a radical transformation, and few companies embody this shift more than Hims & Hers Health, Inc. (NYSE: HIMS). Once dismissed as a...

Via Finterra

Topics Artificial Intelligence Economy

Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock ↗

March 10, 2026

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

Via Stocktwits

Topics Intellectual Property Lawsuit

Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers

March 10, 2026

From Hims & Hers

Via Business Wire

From Red to Green: How Trump's Iran Endgame Sparked a Wall Street Comeback ↗

March 10, 2026

Via Chartmill

Topics Government

HIMS Stock Rockets To Best Day Ever After Novo Nordisk Pact — Wall Street Upgrades Roll In As Shorts Lose $546M In One Day ↗

March 10, 2026

Short interest totalled about $1.39 billion, or roughly 42.83% of the float, according to S3 Partners.

Via Stocktwits

Topics Intellectual Property Lawsuit

Stock Market Today, March 9: Hims & Hers Health Soars on Novo Nordisk Weight-Loss Drug Deal ↗

March 09, 2026

On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player’s GLP-1 strategy, margins, and legal risk profile.

Via The Motley Fool

Topics Intellectual Property Lawsuit Stocks

Top stock movements in today's session. ↗

March 09, 2026

Via Chartmill

These stocks are making the most noise in today's session. ↗

March 09, 2026

Via Chartmill

The Great 2026 Pivot: Tangible Assets Surge as Tech Giants Falter in Massive Sector Rotation

March 09, 2026

The financial landscape on March 9, 2026, has reached a critical tipping point, marking one of the most aggressive sector rotations in modern market history. As technology-heavy indices struggle to...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!

March 09, 2026

Via AB Newswire

Monday's session: top gainers and losers ↗

March 09, 2026

Via Chartmill

Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS

March 09, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy? ↗

March 09, 2026

Hims & Hers stock traded more than 40% higher after the deal was announced.

Via The Motley Fool

Topics Lawsuit

Hims & Hers Stock Pops 40%: Everything You Need to Know ↗

March 09, 2026

Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.

Via The Motley Fool

Topics Lawsuit

Why Hims & Hers Health (HIMS) Stock Is Up Today

March 09, 2026

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 41.7% in the morning session after the company announced a collaboration wi...

Via StockStory

Topics Economy Lawsuit Stocks

Gapping stocks in Monday's session ↗

March 09, 2026

Via Chartmill

The Pivot to Legitimacy: Hims & Hers Health (HIMS) Faces a New Era of Personalized Medicine

March 09, 2026

Date: March 9, 2026Sector: Healthcare TechnologyCompany: Hims & Hers Health, Inc. (NYSE: HIMS) Introduction As of March 9, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at perhaps the most...

Via Finterra

Topics Artificial Intelligence Economy

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

63 64 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.